ACTRN12623001164684 – Assessing treatment effectiveness of the ‘Repurposing-Drugs-in-Oncology’ (ReDO) protocol for cancer: The ReDO cancer treatment study (2023)

Peer-Reviewed Study · Dr Taufiq Binjemain (primary sponsor), Willow Vale Clinic, Queensland; NIIM Human Research Ethics Committee · November 9, 2023

Dr Taufiq Binjemain (primary sponsor), 2023-11-09: An Australian single-arm case series of the 19-item ReDO protocol, in which item 13 is mebendazole or fenbendazole 100 mg twice daily, with patients as their own controls and circulating tumour cells as the primary outcome.

13 Mebendazole / Fenbendazole 100 mg x2

Registry record field, intervention list (unpaginated)

Dr Taufiq Binjemain (primary sponsor), 2023-11-09: An Australian single-arm case series of the 19-item ReDO protocol, in which item 13 is mebendazole or fenbendazole 100 mg twice daily, with patients as their own controls and circulating tumour cells as the primary outcome. Study type: uncontrolled series.